Live Chat
0 ITEMS0

0 ITEMS

৳
0
Dhaka

Selected City: Dhaka

Use my current Location


Change City

EN 

|

 বাং

Dhaka

Use my current Location


Change City

Selected City: Dhaka

Grocery
Pharmacy
Cookups
  • Offers
  • Egg Club
  • Daily Deals
  • Favourites
  • Common Conditions 
  • Sexual Wellness
  • Birth Control Contraceptives
  • Vitamins & Supplements 
  • Medical Devices
  • Medical Accessories
  • Personal Care 
  • Health & Wellness 
  • Baby Care 
  • Premium Care
  • Food Aid
  • Recipes
Help
File a complaint

    Corestin Tablet 10mg

    10 tablets
    ৳250
    0
    in bag

    Product Information

    CORESTIN

    Presentation

    Corestin 5 mg Tablet: Pink, round shaped film-coated tablet each tablet contains Rosuvastatin calcium BP equivalent to

    Rosuvastatin 5 mg.

    Corestin 10 mg Tablet: Pink, shield-shaped, scored on one side, a [https://unimedunihealth.com/wp-content/uploads/2014/04/a.jpg]

    [https://unimedunihealth.com/wp-content/uploads/2014/04/a.jpg] engraved on another side film-coated tablet; each tablet contains

    Rosuvastatin calcium BP equivalent to Rosuvastatin 10 mg.

    Corestin 20 mg Tablet: Pink, diamond-shaped, scored film coated tablet; each tablet contains Rosuvastatin calcium BP equivalent to

    Rosuvastatin 20 mg.

    Indications

    Corestin is indicated for patients with primary hypercholesterolaemia (type lla including heterozygous familial

    hypercholesterolaemia) or mixed dyslipidaemia (type llb) as an adjunct to diet when the response to diet and exercise are

    inadequate.

    Corestin reduces elevated LDL-cholesterol, total cholesterol, triglycerides, and ApoB, and increases HDL-cholesterol

    Corestin is also indicated in patients with homozygous familial hypercholesterolaemia, either alone or as an adjunct to diet and

    other lipid-lowering treatments (e.g. LDL apheresis)

    Dosage & administration

    Before initiating treatment with Corestin, the patient should be placed on a standard cholesterol-lowering diet that should

    continue during treatment. The dose of Corestin should be individualised according to the goal of therapy and patient response,

    using current consensus guidelines.

    The usual start dose is Corestin 10 mg once daily and the majority of patients are controlled at this dose. A dose adjustment to

    20 mg can be made after 4 weeks if necessary Corestin at a dose of 40 mg should only be used in patients with severe

    hypercholesterolaemia (including those with familial hypercholesterolaemia) who do not achieve their treatment goal on 20 mg.

    Corestin may be given at any time of day, with or without food.

    Use in children

    Paediatric experience is limited to a small number of children (aged 8 years or above) with homozygous familial

    hypercholesterolaemia. Use in children should be supervised by specialists.

    Use in the elderly

    No dose adjustment is necessary

    Dosage in patients with renal insufficiency

    No dose adjustment is necessary for patients with mild to moderate renal impairment. For patients with severe renal impairment

    (CrCl <30 m/min) the dose of Corestin should not exceed 10 mg once daily

    Dosage in patients with hepatic impairment

    No dose adjustment is necessary for patients with mild to moderate hepatic impairment Increased systemic exposure to rosuvastatin

    has been observed in patients with severe hepatic impairment, therefore, the dose of Corestin should not exceed 20 mg once daily.

    Interactions requiring dose adjustments

    Gemfibrozil: Increased systemic exposure to rosuvastatin has been observed in subjects taking concomitant Corestin and

    gemfibrozil. Patients taking this combination should not exceed a dose of Corestin 10 mg once daily.

    Contra indications, warnings etc.

    Contra indications: Rosuvastatin is contraindicated in patients:-

    * with hypersensitivity to any component of this product.

    * with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase

    elevation exceeding 3 x the upper limit of normal.

    * with myopathy.

    * receiving concomitant cyclosporin.

     

    Warnings and Precautions

    As with other HMG-CoA reductase inhibitors, Corestin should be used with caution in patients who consume excessive quantities of

    alcohol and/or have a history of liver disease. It is recommended that liver function tests be carried out prior to, and 3 months

    following, the initiation of treatment with Rosuvastatin. Rosuvastatin should be discontinued or the dose reduced it the level of

    serum transaminases is greater than 3 times the upper limit of normal.

    Patients should be asked to report inexplicable muscle pain or weakness immediately, particularly if associated with malaise or

    fever. CK levels should be measured in these patients. Rosuvastatin therapy should be discontinued if CK levels are markedly

    elevated (10xULN) or, If on clinical grounds, myopathy is diagnosed or suspected.

    In Rosuvastatin trials there was no evidence of increased skeletal muscle effects in the small number of patients dosed with

    Corestin and concomitant therapy.

    Corestin should not be used in any patient with an acute, serious condition suggestive of myopathy or predisposing to the

    development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic,

    endocrine and electrolyte disorders, or uncontrolled seizures).

    Proteinuria, detected by dipstick testing and mostly tubular in origin has been observed in patients treated with renal disease.

     

     

    Drug Interactions

    Vitamin K antagonists: As with other HMG-CoA reductase inhibitors, the initiation of treatment or dosage up-titration of Corestin

    in patients treated concomitantly with vitamin K antagonists (e.g. warfarin) may result in an increase in INR. Discontinuation or

    down-titration of Corestin may result in a decrease in INR. In such situations, appropriate monitoring of INR is desirable.

    Gemfibrozil: Concomitant use of Rosuvastatin and gemfibrozil resulted in a 2-fold increase in rosuvastatin Cmax and AUC.

    Cyclosporin: During concomitant treatment with Rosuvastatin and cyclosporin, rosuvastatin plasma levels were on average 7 times

    higher than those observed in healthy volunteers. Concomitant administration of Corestin and cyclosporin did not affect plasma

    concentrations of cyclosporin. Antacid: The simultaneous dosing of Corestin with an antacid suspension containing aluminum and

    magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%. This effect was mitigated

    when the antacid was dosed 2 hours after Corestin. Cytochrome P450 enzymes: Results from in vitro and in vivo studies show that

    rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. No interactions have been observed between

    rosuvastatin and either fluconazole or ketoconazole. Erythromycin: Concomitant use of Rosuvastatin and erythromycin resulted in a

    20% decrease in AUC (0-t) and a 30% decrease in Cmax of rosuvastatin. This interaction may be caused by the increase in gut

    motility caused by erythromycin. Oral Contraceptive: Concomitant use of Rosuvastatin and an oral contraceptive resulted in an

    increase in ethinyloestradiol and norgestrel AUC of 26% and 34%, respectively. These increased plasma levels should be considered

    when selecting oral contraceptive doses. Other medications: There were no clinically relevant interactions with digoxin,

    fenofibrate, antihypertensive agents, antidiabetic agents, and hormone replacement therapy.

    Use during pregnancy and lactation

    Rosuvastatin should not be used during pregnancy or lactation as the safety of Rosuvastatin during pregnancy and whilst

    breastfeeding has not been established.

    Undesirable effects

    The adverse events seen with Rosuvastatin are generally mild and transient. In controlled clinical trials, less than 4% of

    Rosuvastatin treated patients were withdrawn due to adverse events. Headache, dizziness, constipation, nausea, abdominal pain,

    myalgia, asthenia.

    Overdose

    There is no specific treatment in the event of an overdose. In the event of overdose, the patient should be treated

    symptomatically and supportive measures instituted as required. Liver function and CK levels should be monitored. Haemodialysis is

    unlikely to be of benefit.

    Mechanism of action

    Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts

    3-hydroxy-3-methyIgIutaryI coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of rosuvastatin is

    the liver, the target organ for cholesterol-lowering. Corestin increases the number of hepatic LDL receptors on the cell surface,

    enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL

    and LDL particles. A therapeutic response to Corestin is evident within 1 week of commencing therapy and 90% of the maximum

    response is usually achieved in 2 weeks. The maximum response is usually achieved by 4 weeks and is maintained after that.

    Pharmacokinetic properties

    Absorption: Maximum rosuvastatin plasma concentrations are achieved approximately 5 hours after oral administration. The absolute

    bioavailability is approximately 20%. Distribution: Rosuvastatin is taken up extensively by the liver which is the primary site of

    cholesterol synthesis and LDL-C clearance. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin.

    Metabolism: Rosuvastatin undergoes limited metabolism (approximately 10%), mainly to the N- desmethyl metabolite and the lactone

    metabolite. The N-desmethyl metabolite is approximately 50% less active than rosuvastatin whereas the lactone form is considered

    clinically inactive. Rosuvastatin accounts for greater than 90% of the circulating HMG-CoA reductase inhibitor activity.

    Excretion: Approximately 90% of rosuvastatin is excreted as unchanged drug in the faeces and the remaining part is excreted in the

    urine. The plasma elimination half-life is approximately 19 hours. The elimination half-life does not increase at higher doses.

    Pharmaceutical precautions

    Store in a cool and dry place, protected from light

    Packaging quantities

    Corestin 5 mg Tablet: Carton containing 30 tablets in Alu-Alu blister.

    Corestin 10 mg Tablet Carton containing 30 tablets in Alu-Alu blister.

    Corestin 20 mg Tablet Carton containing 10 tablets in Alu-Alu blister.

     

    Manufactured by

    UniMed UniHealth Pharmaceuticals Limited

    B.K. Bari, Gazipur, Bangladesh

    Registered Trademark

    • 30 minute delivery
    • Cash on delivery
    • Pay with

    Chaldal logo

    Chaldal.com is an online shop available in Dhaka, Chattogram, Jashore, Khulna and Narayanganj. We believe time is valuable to our fellow residents, and that they should not have to waste hours in traffic, brave bad weather and wait in line just to buy basic necessities like eggs! This is why Chaldal delivers everything you need right at your door-step and at no additional cost.

    Customer Service

    • Contact Us
    • FAQ

    About Chaldal

    • Privacy Policy
    • Terms of Use

    For Business

    • Corporate
    16710
    or email[email protected]